Aloevera
Phase 3Small molecule
Aloevera is one of 58 small molecule programs targeting Xerostomia. It is currently in Phase 3.
3
Indications
3
Total Trials
0
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
65 competitors in Chronic Periodontitis
#DrugCompanyPhaseTrials
1Zocor
OOrganon and Co
Approved
Crestor
AstraZenecaPhase 3
Alendronate Sodium
Mylan Pharmaceuticals IncApproved
Propolis
IIndonesia University
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Glucophage
EMD SeronoPhase 3
Fosamax
OOrganon and Co
Phase 3
IC-Green
CCHX Technologies Inc.
Phase 3
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Spirulina
TTanta University
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Oral Submucous Fibrosis1 trial
Evaluation of Efficacy of Aloevera in the Treatment of Oral Submucous Fibrosis- A Clinical Study
Completed·TThe Oxford Dental College, Hospital and Research Center, Bangalore, India·Phase 3·NCT02714543·74 enrolled
Xerostomia1 trial
Aloe Vera Versus Thyme Honey Mouthwash in Management of Xerostomia in Type 2 Diabetics
Unknown status·—·Phase 3·NCT05885906·45 enrolled
Chronic Periodontitis1 trial
Locally Delivered Metformin and Aloe Vera for Treatment of Intrabody Defects in Chronic Periodontitis
Completed·GGovernment Dental College and Research Institute, Bangalore·Phase 2/3·NCT03204071·90 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aloevera. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details